Literature DB >> 931372

Pharmacokinetics of cefaclor in normal subjects and patients with chronic renal failure.

R Bloch, J J Szwed, R S Sloan, F C Luft.   

Abstract

We studied the pharmacokinetics of cefaclor, a new cephalosporin antibiotic, in normal subjects and subjects with chronic renal failure. Cefaclor was largely, but not entirely, eliminated by the kidneys. The cefaclor half-life in normal subjects was 40 to 60 min; in subjects with essentially no renal function, it increased to 3 h. In normal subjects, 50 to 70% of a 250-mg dose was excreted in the urine within 8 h. The linear relationship between the elimination constant and creatinine clearance allowed the construction of a useful dosage modification nomogram.

Entities:  

Mesh:

Substances:

Year:  1977        PMID: 931372      PMCID: PMC430012          DOI: 10.1128/AAC.12.6.730

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  5 in total

1.  Determination of creatinine in small quantities of plasma. Observations on two methods.

Authors:  E MARTINEZ; P D DOOLAN
Journal:  Clin Chem       Date:  1960-06       Impact factor: 8.327

2.  Metabolism of (14C) cefaclor, a cephalosporin antibiotic, in three species of laboratory animals.

Authors:  H R Sullivan; S L Due; D L Kau; J F Quay; W Miller
Journal:  Antimicrob Agents Chemother       Date:  1976-10       Impact factor: 5.191

3.  Antimicrobial dosage in renal failure: a unifying nomogram.

Authors:  C S Bryan; W J Stone
Journal:  Clin Nephrol       Date:  1977-02       Impact factor: 0.975

4.  Pharmacokinetics in renal disease.

Authors:  G Levy
Journal:  Am J Med       Date:  1977-04       Impact factor: 4.965

5.  Rapid detection of ampicillin-resistant Haemophilus influenzae and their susceptibility to sixteen antibiotics.

Authors:  R B Kammer; D A Preston; J R Turner; L C Hawley
Journal:  Antimicrob Agents Chemother       Date:  1975-07       Impact factor: 5.191

  5 in total
  9 in total

1.  [Serum and tissue concentrations after a single dose of cefaclor].

Authors:  R Plaue; O Müller; K Fabricius; R O Bethke
Journal:  Infection       Date:  1979       Impact factor: 3.553

2.  Cefaclor: summary of clinical experience.

Authors:  R B Kammer; L J Short
Journal:  Infection       Date:  1979       Impact factor: 3.553

3.  Cefaclor pharmacokinetic parameters: serum concentrations determined by a new high-performance liquid chromatographic technique.

Authors:  J C Rotschafer; K B Crossley; T S Lesar; D Zaske; K Miller
Journal:  Antimicrob Agents Chemother       Date:  1982-01       Impact factor: 5.191

4.  Comparative pharmacokinetics of cephalexin, cefaclor, cefadroxil, and CGP 9000.

Authors:  H Lode; R Stahlmann; P Koeppe
Journal:  Antimicrob Agents Chemother       Date:  1979-07       Impact factor: 5.191

Review 5.  Clinical pharmacokinetics of antibiotics in patients with impaired renal function.

Authors:  W L St Peter; K A Redic-Kill; C E Halstenson
Journal:  Clin Pharmacokinet       Date:  1992-03       Impact factor: 6.447

6.  Pharmacokinetics of cefaclor and cephalexin: dosage nomograms for impaired renal function.

Authors:  D A Spyker; B L Thomas; M A Sande; W K Bolton
Journal:  Antimicrob Agents Chemother       Date:  1978-08       Impact factor: 5.191

7.  Pharmacokinetics of cefaclor in renal failure: effects of multiple doses and hemodialysis.

Authors:  D A Spyker; L L Gober; W M Scheld; M A Sande; W K Bolton
Journal:  Antimicrob Agents Chemother       Date:  1982-02       Impact factor: 5.191

8.  Elimination of cefroxadine (CGP-9000) from patients undergoing dialysis.

Authors:  M J Nieto; J M Lanao; A Dominguez-Gil; J M Tabernero; J F Macias
Journal:  Eur J Clin Pharmacol       Date:  1983       Impact factor: 2.953

9.  Population Pharmacokinetic Analysis of Cefaclor in Healthy Korean Subjects.

Authors:  Seung-Hyun Jeong; Ji-Hun Jang; Hea-Young Cho; Yong-Bok Lee
Journal:  Pharmaceutics       Date:  2021-05-19       Impact factor: 6.321

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.